Edoxaban, an oral factor Xa inhibitor, and PAR2 deficiency improved glomerulosclerosis and urinary albumin excretion, and this was accompanied by a decrease in renal-inflammation–fibrosis-related markers in this model [35]. Here, F2RL1 is linked to glomerulosclerosis.